Home › Compare › MCTZF vs ABBV
MCTZF yields 1212.12% · ABBV yields 3.06%● Live data
📍 MCTZF pulled ahead of the other in Year 1
Combined, MCTZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MCTZF + ABBV for your $10,000?
MCOT Public Company Limited, together with its subsidiaries, engages in the multi-media business in Thailand. It operates through Television and News Services, Radio Services, Engineering Services, New Business Services segments. The company provides digital terrestrial television broadcasting network services comprising high definition variety and standard definition family channels with programs comprising news and situation report, entertainment, edutainment, general knowledge, and sports; and engages in the production, marketing, and management of radio business comprising 62 central and regional radio stations broadcasting in FM and AM frequencies that broadcasts various informative and entertaining radio programs in the areas of politics, economy, society, foreign affairs, technology, music, sports, tourism, health and recreation activities, and news reports and analyses, as well as knowledge and entertainment programs of local interest. It also engages in the production, collection, storage, and dissemination of news and information through various media platforms, including television and radio, online digital media, social media and SMS via mobile phones, and news exchange with foreign alliances; provides satellite TV rental services to other satellite TV operators; engages in the production and dissemination of contents through online platforms, including video, still image, sound, and articles for live and on-demand consumption; and operates mass media training institute that provides a range of mass media training courses. The company was founded in 1977 and is based in Bangkok, Thailand.
Full MCTZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.